has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of metastatic bladder or urinary tract cancer.

In urothelial bladder cancer, increased T cell infiltration ... the response rate reported was 23% with PD-L1 inhibitor, ...

Keytruda is already approved for adjuvant treatment after resection and platinum-based chemotherapy for stage IB-IIIA NSCLC, as is Roche’s Tecentriq (atezolizumab), with a similar indication ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors: 72-year-old patient with urothelial bladder cancer who had previously received gemcitabine plus ...

Opens in a new tab or window Jazz Pharmaceuticals announced that adding lurbinectedin (Zepzelca) to atezolizumab (Tecentriq ... in non-muscle invasive bladder cancer, including complete responses ...

There are many treatment options for bladder cancer, which vary depending on the stage and type of bladder cancer you have, your overall health, and your preferences. These include various types ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...